What is HC Wainwright's Forecast for CMPX Q2 Earnings?

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Stock analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Compass Therapeutics in a note issued to investors on Thursday, May 8th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.12). HC Wainwright currently has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics' Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.48) EPS and FY2028 earnings at ($0.18) EPS.

Several other research firms also recently weighed in on CMPX. Wedbush restated an "outperform" rating and issued a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Guggenheim reduced their target price on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a report on Friday, May 9th. Piper Sandler started coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective for the company. Leerink Partnrs upgraded shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. Finally, Jefferies Financial Group lifted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday, February 10th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $13.13.

Compass Therapeutics Price Performance

CMPX remained flat at $2.00 on Monday. 1,312,346 shares of the company's stock traded hands, compared to its average volume of 908,747. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08. The business has a 50-day simple moving average of $1.97 and a two-hundred day simple moving average of $2.10. The firm has a market cap of $276.57 million, a price-to-earnings ratio of -5.41 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12).

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its position in shares of Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock valued at $187,000 after acquiring an additional 3,822 shares during the period. Invesco Ltd. lifted its stake in Compass Therapeutics by 11.3% during the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company's stock valued at $57,000 after acquiring an additional 4,018 shares during the period. Bank of New York Mellon Corp lifted its stake in Compass Therapeutics by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company's stock valued at $463,000 after acquiring an additional 5,590 shares during the period. ProShare Advisors LLC lifted its stake in Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after acquiring an additional 9,451 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in Compass Therapeutics by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock valued at $69,000 after acquiring an additional 11,326 shares during the period. Institutional investors and hedge funds own 68.43% of the company's stock.

Insider Buying and Selling

In other news, insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the purchase, the insider now directly owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is currently owned by company insiders.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.